BOISE, ID – MARCH 14, 2024 – The Fatty Liver Foundation (FLF) heralds a significant milestone in the field of liver health with the U.S. Food and Drug Administration’s (FDA) approval of REZDIFFRA™ (resmetirom), developed by Madrigal Pharmaceuticals, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). This landmark approval paves the way for the first-ever medication for adults with fibrosis stage 2 or 3 due to MASH, marking a watershed moment in the pursuit of effective treatments. REZDIFFRA™ has been recognized by the FDA through breakthrough therapy and priority review designations for this crucial indication.

Below is a link to our press release.  We will publish more information in coming days but this is a great day for NASH patients.

a_new_dawn_in_liver_health_fatty_liver_foundation_applauds_breakthrough_fda_approval_of_rezdiffra_resmetirom_for_mash_treatment

This is the notice by FDA of the approval

(6) U.S. FDA on X: "Today, FDA approved a medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. https://t.co/1W5ImNdh0U https://t.co/tHei4N9aH0" / X (twitter.com)

I look forward to providing the nuts and bolts about how the drug will be used but for now wooo/hooo.